Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dentistry
Volume 2016 (2016), Article ID 1095927, 6 pages
http://dx.doi.org/10.1155/2016/1095927
Case Report

Gingival Enlargement Induced by Felodipine Resolves with a Conventional Periodontal Treatment and Drug Modification

1DB Dental, Corner Tydeman & Pensioner Guard Roads, Perth, WA 6159, Australia
2Irwin Dental Centre, Irwin Barracks, Perth, WA 6010, Australia
3General Dental Practice, School of Dentistry and Oral Health, Griffith University, Gold Coast, QLD 4222, Australia

Received 5 January 2016; Revised 3 February 2016; Accepted 7 February 2016

Academic Editor: Ronald S. Brown

Copyright © 2016 Nabil Khzam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Abdollahi and M. Radfar, “A review of drug induced oral reactions,” Journal of Contemporary Dental Practice, vol. 4, no. 1, pp. 10–31, 2003. View at Google Scholar · View at Scopus
  2. A. A. Fay, K. Satheesh, and R. Gapski, “Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient,” Journal of Periodontology, vol. 76, no. 7, pp. 1217–1222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. M. Hassell and G. H. Gilbert, “Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement,” The American Journal of Pathology, vol. 112, no. 2, pp. 218–223, 1983. View at Google Scholar · View at Scopus
  4. I. Casetta, E. Granieri, M. Desiderá et al., “Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy,” Neuroepidemiology, vol. 16, no. 6, pp. 296–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Brunsvold, J. Tomasovic, and D. Ruemping, “The measured effect of phenytoin withdrawal on gingival hyperplasia in children,” ASDC Journal of Dentistry for Children, vol. 52, no. 6, pp. 417–421, 1985. View at Google Scholar · View at Scopus
  6. E. M. Rateitschak-Pluss, A. Hefti, R. Lortscher, and G. Thiel, “Initial observation that cyclosporin-A induces gingival enlargement in man,” Journal of Clinical Periodontology, vol. 10, no. 3, pp. 237–246, 1983. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Pisanty, E. Rahamim, D. Ben-Ezra, and S. Shoshan, “Prolonged systemic administration of cyclosporin A affects gingival epithelium,” Journal of Periodontology, vol. 61, no. 2, pp. 138–141, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. C. G. Daly, “Resolution of cyclosporin A (CsA)-induced gingival enlargement following reduction in CsA dosage,” Journal of Clinical Periodontology, vol. 19, no. 2, pp. 143–145, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Barak, I. S. Engelberg, and J. Hiss, “Gingival hyperplasia caused by nifedipine—histopathologic findings,” Journal of Periodontology, vol. 58, no. 9, pp. 639–642, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. G. E. Romanos, C. Schroter-Kermani, N. Hinz, D. Herrmann, J. R. Strub, and J. P. Bernimoulin, “Extracellular matrix analysis of nifedipine-induced gingival overgrowth: immunohistochemical distribution of different collagen types as well as the glycoprotein fIbronectin,” Journal of Periodontal Research, vol. 28, no. 1, pp. 10–16, 1993. View at Publisher · View at Google Scholar
  11. J. Miranda, L. Brunet, P. Roset, L. Berini, M. Farré, and C. Mendieta, “Prevalence and risk of gingival enlargement in patients treated with nifedipine,” Journal of Periodontology, vol. 72, no. 5, pp. 605–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. H. E. Pernu, K. Oikarinen, J. Hietanen, and M. Knuuttila, “Verapamil-induced gingival overgrowth: a clinical, histologic, and biochemic approach,” Journal of Oral Pathology and Medicine, vol. 18, no. 7, pp. 422–425, 1989. View at Publisher · View at Google Scholar · View at Scopus
  13. C. S. Miller and D. D. Damm, “Incidence of verapamil-induced gingival hyperplasia in a dental population,” Journal of Periodontology, vol. 63, no. 5, pp. 453–456, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. A. V. Mehta, B. Chidambaram, and A. C. O'Riordan, “Verapamil-induced gingival hyperplasia in children,” American Heart Journal, vol. 124, no. 2, pp. 535–536, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Giustiniani, F. R. della Cuna, and M. Marieni, “Hyperplastic gingivitis during diltiazem therapy,” International Journal of Cardiology, vol. 15, no. 2, pp. 247–249, 1987. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Fattore, M. Stablein, G. Bredfeldt, T. Semla, M. Moran, and J. M. Doherty-Greenberg, “Gingival hyperplasia: a side effect of nifedipine and diltiazem,” Special Care in Dentistry, vol. 11, no. 3, pp. 107–109, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Tavassoli, N. Yamalik, F. Çaǧlayan, G. Çaǧlayan, and K. Eratalay, “The clinical effects of nifedipine on periodontal status,” Journal of Periodontology, vol. 69, no. 2, pp. 108–112, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Prisant and W. Herman, “Calcium channel blocker induced gingival overgrowth,” Journal of Clinical Hypertension, vol. 4, no. 4, pp. 310–311, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Sucu, M. Yuce, and V. Davutoglu, “Amlodipine-induced massive gingival hypertrophy,” Canadian Family Physician, vol. 57, no. 4, pp. 436–437, 2011. View at Google Scholar · View at Scopus
  20. L. Kuru, S. Yilmaz, B. Kuru, K. N. Köse, and Ü. Noyan, “Expression of growth factors in the gingival crevice fluid of patients with phenytoin-induced gingival enlargement,” Archives of Oral Biology, vol. 49, no. 11, pp. 945–950, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Varnfield and S. J. Botha, “Drug-induced gingival hyperplasia—a review,” SADJ, vol. 55, no. 11, pp. 632–641, 2000. View at Google Scholar · View at Scopus
  22. J. M. Thomason, R. A. Seymour, J. S. Ellis et al., “Iatrogenic gingival overgrowth in cardiac transplantation,” Journal of Periodontology, vol. 66, no. 8, pp. 742–746, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. López-Pintor, G. Hernández, L. de Arriba, J. M. Morales, C. Jiménez, and A. de Andrés, “Amlodipine and nifedipine used with cyclosporine induce different effects on gingival enlargement,” Transplantation Proceedings, vol. 41, no. 6, pp. 2351–2353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ono, S. Tanaka, R. Takeuchi et al., “Prevalence of amlodipine-induced gingival overgrowth,” International Journal of Oral-Medical Sciences, vol. 9, no. 2, pp. 96–100, 2010. View at Publisher · View at Google Scholar
  25. H. Matsumoto, R. Takeuchi, M. Ono, Y. Akimoto, N. Kobayashi, and A. Fujii, “Drug-induced gingival overgrowth and its tentative pharmacotherapy,” Japanese Dental Science Review, vol. 46, no. 1, pp. 11–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. Van Der Krogt, R. Brand, and E. C. Dawson, “Amlodipine versus extended-release felodipine in general practice: a randomized, parallel-group study in patients with mild-to-moderate hypertension,” Current Therapeutic Research—Clinical and Experimental, vol. 57, no. 3, pp. 145–158, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. F. H. H. Leenen and D. L. Holliwell, “Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy,” The American Journal of Cardiology, vol. 69, no. 6, pp. 639–645, 1992. View at Publisher · View at Google Scholar · View at Scopus
  28. E. E. van der Wall, D. B. Tuinzing, and J. Hes, “Gingival hyperplasia induced by nifedipine, an arterial vasodilating drug,” Oral Surgery, Oral Medicine, Oral Pathology, vol. 60, no. 1, pp. 38–40, 1985. View at Publisher · View at Google Scholar · View at Scopus
  29. E. B. Nery, R. G. Edson, K. K. Lee, V. K. Pruthi, and J. Watson, “Prevalence of nifedipine-induced gingival hyperplasia,” Journal of Periodontology, vol. 66, no. 7, pp. 572–578, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Gong, J. Lu, X. Ding, and Y. Yu, “Effect of adjunctive roxithromycin therapy on interleukin-1β, transforming growth factor-β1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth,” Journal of Periodontal Research, vol. 49, no. 4, pp. 448–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. Ø. Fardal and H. Lygre, “Management of periodontal disease in patients using calcium channel blockers—gingival overgrowth, prescribed medications, treatment responses and added treatment costs,” Journal of Clinical Periodontology, vol. 42, no. 7, pp. 640–646, 2015. View at Publisher · View at Google Scholar
  32. R. Agnihotri, G. S. Bhat, and K. M. Bhat, “Amlodipine-induced gingival overgrowth: considerations in a geriatric patient,” Geriatrics and Gerontology International, vol. 11, no. 3, pp. 365–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Bhatia, A. Mittal, A. K. Parida, R. Talwar, and U. Kaul, “Amlodipine induced gingival hyperplasia: a rare entity,” International Journal of Cardiology, vol. 122, no. 3, pp. e23–e24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. R. S. Brown and P. R. Arany, “Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis,” Oral Diseases, vol. 21, no. 1, pp. e51–e61, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Joshi and S. Bansal, “A rare case report of amlodipine-induced gingival enlargement and review of its pathogenesis,” Case Reports in Dentistry, vol. 2013, Article ID 138248, 3 pages, 2013. View at Publisher · View at Google Scholar
  36. P. Westbrook, E. M. Bednarczyk, M. Carlson, H. Sheehan, and N. F. Bissada, “Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine,” Journal of Periodontology, vol. 68, no. 7, pp. 645–650, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Hernández Vallejo, L. Arriba, M. C. Frías et al., “Conversion from Cyclosporin A to Tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series,” Journal of Periodontology, vol. 74, no. 12, pp. 1816–1823, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Waters, J. Ashford, B. Jäger, S. Wonnacott, and C. N. Verboom, “Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension—results of the TOPIC (Trial Of Physiotens In Combination) Study,” Journal of Clinical and Basic Cardiology, vol. 2, no. 2, pp. 219–224, 1999. View at Google Scholar · View at Scopus
  39. P. Chrisp and D. Faulds, “Moxonidine: a review of its pharmacology, and therapeutic use in essential hypertension,” Drugs, vol. 44, no. 6, pp. 993–1012, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Ilgenli, G. Atilla, and H. Baylas, “Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results,” Journal of Periodontology, vol. 70, no. 9, pp. 967–972, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Schachter, “Moxonidine: a review of safety and tolerability after seven years of clinical experience,” Journal of Hypertension Supplement, vol. 17, no. 3, pp. S37–S39, 1999. View at Google Scholar · View at Scopus
  42. M. K. Pöyhönen-Alho, K. Manhem, P. Katzman et al., “Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women,” Journal of Hypertension, vol. 26, no. 12, pp. 2445–2449, 2008. View at Publisher · View at Google Scholar · View at Scopus